



(51) International Patent Classification:

C07K 14/015 (2006.01) *C12N 5/10* (2006.01)
C12N 15/35 (2006.01) *C12N 15/864* (2006.01)
C12N 15/85 (2006.01) *A61K 48/00* (2006.01)

(21) International Application Number:

PCT/US2019/025617

(22) International Filing Date:

03 April 2019 (03.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/652,111	03 April 2018 (03.04.2018)	US
62/776,814	07 December 2018 (07.12.2018)	US
62/819,388	15 March 2019 (15.03.2019)	US

(71) Applicant: **STRIDE BIO, INC.** [US/US]; 701 W. Main Street, Suite 200, Durham, North Carolina 27701 (US).

(72) Inventors: **MCCOY, Daniel**; 7 Wythebrook Lane, Durham, North Carolina 27713 (US). **BERRY, Garrett E.**; 4812 Swanns Mill Drive, Durham, North Carolina 27704 (US).

(74) Agent: **TUSCAN, Michael** et al.; COOLEY LLP, 1299 Pennsylvania Ave. Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODY-EVADING VIRUS VECTORS




Fig. 5

(57) Abstract: The present disclosure provides recombinant AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the recombinant AAV capsid proteins. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject *in vivo*.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*